



THEME 3

THEME #3—METASTATIC HER2-AMPLIFIED BREAST CANCER: THERAPEUTIC OPTIONS

- 69-year-old woman with left breast cancer
- Invasive ductal carcinoma, grade 3, T = 2.5 cm, ER 50%, PR 40%, 1/15 lymph nodes positive, HER2 IHC 3+
- Concomitant diseases: Hypertension (medically well-controlled) and rheumatoid arthritis
- Treatment: Breast conserving surgery, radiotherapy to left breast; anthracycline-based and taxane-based adjuvant chemotherapy followed by trastuzumab (HERA approach) and tamoxifen

FIRST VARIATION—DISEASE PROGRESSION FOLLOWING ADJUVANT TRASTUZUMAB: WHAT'S NEXT?

Discussant: Angelo Di Leo, MD, PhD

After a disease-free interval of 3 years, progression of disease was noted:

- Left supraclavicular node (cytology)
- Lung
- ECOG performance status = 1; LVEF borderline (ECHO 50%)

Would you perform a biopsy of the supraclavicular node to reassess ER/PR and HER2 status in this patient?

1. Yes
2. No

Biopsy was performed and metastatic tumor is endocrine-responsive (ER 60%, PR 40%) and HER2 IHC 3+.

Which of the following treatment options would you recommend for this asymptomatic patient?

1. Trastuzumab + anastrozole
2. Trastuzumab + weekly paclitaxel
3. Lapatinib + letrozole
4. Lapatinib + capecitabine
5. Lapatinib + paclitaxel

SECOND VARIATION—WHAT IF PROGRESSION OCCURS DURING TRASTUZUMAB?

Discussant: José Baselga, MD

Patient is treated with adjuvant anthracycline-based and taxane-based therapy followed by trastuzumab (HERA approach) and tamoxifen, but progressed in left supraclavicular node, lung, and liver during trastuzumab therapy. Biopsy of the supraclavicular node confirmed HER2-positive disease but hormonal receptors were negative (less than 10%), LVEF borderline (ECHO = 50%).

What will be your treatment recommendation now?

1. Lapatinib + capecitabine
2. Lapatinib + trastuzumab
3. Clinical trial of anti-HER2 therapy and an anti-angiogenic agent
4. Clinical trial of pertuzumab + trastuzumab
5. Clinical trial of neratinib
6. Clinical trial with RAD001 (everolimus) + weekly paclitaxel + trastuzumab
7. Clinical trial with tanespimycin (Hsp90) + trastuzumab
8. Clinical trial of trastuzumab-DM1